Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
WIRB-Copernicus Group (WCG)
WIRB-Copernicus Group (WCG)
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
WCG Clinical Services Division opens office in Japan
Its expanded presence in the Asia-Pacific region will strengthen its ability to support increasingly complex, global clinical trials
Finance
WIRB-Copernicus Group clinical services division acquires ACI Clinical
WCG Clinical Services Division expands portfolio to include specialist in endpoint adjudication and data monitoring safety committees
Regulatory
WCG expands portfolio to include drug safety solution provider
WIRB Copernicus Group (WCG) announced its acquisition of Vigilare International
Media
WCG’S MedAvante-ProPhase hires business leaders to grow and improve clinical trial data
Regulatory
New tool to better inform patients about clinical trials
WIRB-Copernicus Group, provider of solutions to measurably improve the quality and efficiency of clinical research has acquired Patient Genesis’ ConsentNow eConsent technology
Regulatory
WIRB-Copernicus Group celebrates IBC review milestone
WIRB-Copernicus IRB Group announced its IBC Services has achieved a major milestone in administering 4000 convened IBC meetings globally
Regulatory
WIRB-Copernicus Group acquires MedAvante and ProPhase
Names Jeffrey Litwin as the Chief Executive Officer (CEO) of the combined company
Subscribe now